These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 29265719)

  • 1. Hepatitis C virus eradication by direct antiviral agents improves glucose tolerance and reduces post-load insulin resistance in nondiabetic patients with genotype 1.
    Salomone F; Catania M; Montineri A; Bertino G; Godos J; Rizzo L; Magrì G; Li Volti G
    Liver Int; 2018 Jul; 38(7):1206-1211. PubMed ID: 29265719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of type 2 diabetes mellitus and glucose abnormalities in patients with chronic hepatitis C infection by response to treatment: results of a cohort study.
    Giordanino C; Bugianesi E; Smedile A; Ciancio A; Abate ML; Olivero A; Pellicano R; Cassader M; Gambino R; Bo S; Ciccone G; Rizzetto M; Saracco G
    Am J Gastroenterol; 2008 Oct; 103(10):2481-7. PubMed ID: 18702647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. INSULIN RESISTANCE REDUCTION AFTER SUSTAINED VIROLOGICAL RESPONSE WITH DIRECT ACTING ANTIVIRAL:NOT EVERY POPULATION IMPROVES.
    Andrade VG; Yamashiro FDS; Oliveira CV; Moreira A; Winckler FC; Silva GF
    Arq Gastroenterol; 2018; 55(3):274-278. PubMed ID: 30540091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis.
    Petta S; Adinolfi LE; Fracanzani AL; Rini F; Caldarella R; Calvaruso V; Cammà C; Ciaccio M; Di Marco V; Grimaudo S; Licata A; Marrone A; Nevola R; Pipitone RM; Pinto A; Rinaldi L; Torres D; Tuttolomondo A; Valenti L; Fargion S; Craxì A
    J Hepatol; 2018 Jul; 69(1):18-24. PubMed ID: 29505844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement of insulin sensitivity in diabetic and non diabetic patients with chronic hepatitis C treated with direct antiviral agents.
    Gualerzi A; Bellan M; Smirne C; Tran Minh M; Rigamonti C; Burlone ME; Bonometti R; Bianco S; Re A; Favretto S; Bellomo G; Minisini R; Carnevale Schianca GP; Pirisi M
    PLoS One; 2018; 13(12):e0209216. PubMed ID: 30571711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosis.
    Asselah T; Bourgeois S; Pianko S; Zeuzem S; Sulkowski M; Foster GR; Han L; McNally J; Osinusi A; Brainard DM; Subramanian GM; Gane EJ; Feld JJ; Mangia A
    Liver Int; 2018 Mar; 38(3):443-450. PubMed ID: 28756625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis C virus eradication with direct-acting antiviral improves insulin resistance.
    Russo FP; Zanetto A; Gambato M; Bortoluzzi I; Al Zoairy R; Franceschet E; De Marchi F; Marzi L; Lynch EN; Floreani A; Farinati F; Schaefer B; Burra P; Zoller H; Mega A
    J Viral Hepat; 2020 Feb; 27(2):188-194. PubMed ID: 31596996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Type 2 diabetes mellitus, insulin resistance and hepatocellular carcinoma in chronic hepatitis C patients.
    Lombay B; Szilágyi R; Szalay F
    Orv Hetil; 2019 Oct; 160(40):1591-1602. PubMed ID: 31565976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis C virus clearance by direct-acting antiviral treatments and impact on insulin resistance in chronic hepatitis C patients.
    Adinolfi LE; Nevola R; Guerrera B; D'Alterio G; Marrone A; Giordano M; Rinaldi L
    J Gastroenterol Hepatol; 2018 Jul; 33(7):1379-1382. PubMed ID: 29228501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Virus Elimination by Direct-Acting Antiviral Agents Impacts Glucose Homeostasis in Chronic Hepatitis C Patients.
    Cheng CH; Chu CY; Chen HL; Lin IT; Wu CH; Lee YK; Bair MJ
    Front Endocrinol (Lausanne); 2021; 12():799382. PubMed ID: 35095765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis.
    Jacobson IM; Lawitz E; Kwo PY; Hézode C; Peng CY; Howe AYM; Hwang P; Wahl J; Robertson M; Barr E; Haber BA
    Gastroenterology; 2017 May; 152(6):1372-1382.e2. PubMed ID: 28193518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Viral eradication reduces both liver stiffness and steatosis in patients with chronic hepatitis C virus infection who received direct-acting anti-viral therapy.
    Tada T; Kumada T; Toyoda H; Sone Y; Takeshima K; Ogawa S; Goto T; Wakahata A; Nakashima M; Nakamuta M; Tanaka J
    Aliment Pharmacol Ther; 2018 Apr; 47(7):1012-1022. PubMed ID: 29424449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severity of liver disease predicts the development of glucose abnormalities in patients with chronic hepatitis B or C following achievement of sustained virological response to antiviral therapy.
    Chehadeh W; Al-Nakib W
    J Med Virol; 2009 Apr; 81(4):610-8. PubMed ID: 19235842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-load insulin resistance does not predict virological response to treatment of chronic hepatitis C patients without the metabolic syndrome.
    Fattovich G; Baroni GS; Pasino M; Pierantonelli I; Covolo L; Ieluzzi D; Passigato N; Tonon A; Faraci MG; Guido M; Negro F
    Dig Liver Dis; 2012 May; 44(5):419-25. PubMed ID: 22277808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of amino acid substitutions in hepatitis C virus genotype 1b core region on liver steatosis and glucose tolerance in non-cirrhotic patients without overt diabetes.
    Sumida Y; Kanemasa K; Hara T; Inada Y; Sakai K; Imai S; Yoshida N; Yasui K; Itoh Y; Okanoue T; Yoshikawa T
    J Gastroenterol Hepatol; 2011 May; 26(5):836-42. PubMed ID: 21054524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amelioration of glucose intolerance through directly acting antiviral agents in chronic hepatitis C cirrhotic patients without overt diabetes.
    Jang TY; Lin YH; Liang PC; Yeh ML; Huang CI; Liu TW; Wei YJ; Hsu PY; Yang JF; Hou NJ; Wang CW; Hsieh MY; Lin ZY; Huang CF; Huang JF; Dai CY; Chuang WL; Yu ML
    Kaohsiung J Med Sci; 2022 Sep; 38(9):897-906. PubMed ID: 35670210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of a successful treatment of hepatitis C virus on glyco-metabolic control in diabetic patients: a systematic review and meta-analysis.
    Carnovale C; Pozzi M; Dassano A; D'Addio F; Gentili M; Magni C; Clementi E; Radice S; Fiorina P
    Acta Diabetol; 2019 Mar; 56(3):341-354. PubMed ID: 30478781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvement of glycemic state among responders to Sofosbuvir-based treatment regimens: Single center experience.
    Abdel Alem S; Elsharkawy A; Fouad R; Adel E; Abdellatif Z; Musa S; Nagy A; Hussein MS; Yosry A; Esmat G
    J Med Virol; 2017 Dec; 89(12):2181-2187. PubMed ID: 28688190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simeprevir and daclatasvir for 12 or 24 weeks in treatment-naïve patients with hepatitis C virus genotype 1b and advanced liver disease.
    Hézode C; Almasio PL; Bourgeois S; Buggisch P; Brown A; Diago M; Horsmans Y; Serfaty L; Szalay F; Gaeta GB; Planas R; Schlag M; Lonjon-Domanec I; Omoruyi E; DeMasi R; Zeuzem S
    Liver Int; 2017 Sep; 37(9):1304-1313. PubMed ID: 28135777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained virological response: a milestone in the treatment of chronic hepatitis C.
    Morisco F; Granata R; Stroffolini T; Guarino M; Donnarumma L; Gaeta L; Loperto I; Gentile I; Auriemma F; Caporaso N
    World J Gastroenterol; 2013 May; 19(18):2793-8. PubMed ID: 23687416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.